Boston Scientific Acquires BTG with its Interventional Medicine Portfolio

Shots:

• Boston acquired BTG in all stocks transaction, for ~$1.07/per share at a premium of 36.6%, with total deal value of $4.2B. The transaction is expected to close in H1’19
• The acquisition will strengthen Boston’s peripheral intervention platform with BTG’s minimally-invasive treatments like TheraSphere Y-90 radiotherapy, GALI cryoablation and EKOS Endovascular System for treatment of cancer and vascular diseases
• EKOS system is a FDA approved device used with thrombolytic agents, indicated for pulmonary embolism. TheraSphere Y-90 radiotherapy & GALI system is indicated for liver & renal cancers

Click here to read full press release/ article | Ref: Boston Scientific | Image: BTG International